Gastrointestinal Conditions News

Officials from the Elverta Joint Elementary School District in Sacramento County, California have closed three schools this week due to 38 cases of norovirus among students and faculty.

ATLANTA — More than 7 years after a 7.0-magnitude earthquake set the stage for a cholera outbreak in Haiti, people in the resource-poor West Indies nation are still in danger of being infected, researchers said.

AMSTERDAM — A novel approach for cholestatic pruritus, ileal bile acid transporter inhibition, was associated with improvement in pruritus in nearly three-quarters of children and adolescents, according to data presented at the International Liver Congress.

Today, the FDA has approved Merck and Samsung Bioepis’ infliximab biosimilar for injection, which is known as infliximab-abda (Renflexis). It will maintain the same indications as the reference product.

For the first time, the CDC’s yearly report on foodborne illnesses in the U.S. included infections that were identified only with rapid diagnostic tests, which can speed up treatment for patients but lead to important gaps in data, researchers said.

The FDA has approved sofosbuvir and ledipasvir/sofosbuvir as supplemental applications for the treatment of hepatitis C in children aged 12 to 17 years, according to an FDA news release.

According to a review published in Pediatric Annals, literature provides insight that cyproheptadine, a serotonin antagonist, is potentially effective and safe for the treatment of functional gastrointestinal disorders.

The incidence of inflammatory bowel disease has significantly increased among Canadian children aged younger than 5 years since the turn of the century, according to the results of a population-based study.

Home-based hypnotherapy exercises on a CD were as effective as individual gut-directed hypnotherapy performed by a qualified therapist in children with irritable bowel syndrome or functional abdominal pain syndrome, according to the results of a randomized clinical trial.

The FDA has approved Sovaldi and Harvoni as supplemental applications for the treatment of hepatitis C in children aged 12 to 17 years, according to an FDA news release.